1-(5-iodo-1H-indol-2-yl)ethanone | 1373439-04-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-(5-iodo-1H-indol-2-yl)ethanone
• CAS: 1373439-04-3
• 化学式: C₁₀H₈INO
• 分子量: 285.084
• InChiKey: RPFDYVFXVRSHTP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  32.9
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(5-iodo-1H-indol-2-yl)ethanone 、 5-溴-2-羟基苯并肼 在 溶剂黄146 作用下， 以 乙醇 为溶剂， 以64%的产率得到5-bromo-2-hydroxy-N'-[(1E)-1-(5-iodo-1H-indol-2-yl)ethylidene]benzohydrazide
  参考文献：
  名称：

  Optimization and structure–activity relationships of a series of potent inhibitors of methicillin-resistant Staphylococcus aureus (MRSA) pyruvate kinase as novel antimicrobial agents

  摘要：

  A novel series of hydrazones were synthesized and evaluated as inhibitors of methicillin-resistant Staphylococcus aureus (MRSA) pyruvate kinase (PK). PK has been identified as one of the most highly connected 'hub proteins' in MRSA. PK has been shown to be critical for bacterial survival which makes it a potential target for development of novel antibiotics and the high degree of connectivity implies it should be very sensitive to mutations and thus less able to develop resistance. PK is not unique to bacteria and thus a critical requirement for such a PK inhibitor would be that it does not inhibit the homologous human enzyme(s) at therapeutic concentrations. Several MRSA PK inhibitors (including 8d) were identified using in silico screening combined with enzyme assays and were found to be selective for bacterial enzyme compared to four human PK isoforms (M1, M2, R and L). However these lead compounds did not show significant inhibitory activity for MRSA growth presumably due to poor bacterial cell penetration. Structure-activity relationship (SAR) studies were carried out on 8d and led us to discover more potent compounds with enzyme inhibiting activities in the low nanomolar range and some were found to effectively inhibit bacteria growth in culture with minimum inhibitory concentrations (MIC) as low as 1 mu g/mL. These inhibitors bind in two elongated flat clefts found at the minor interfaces in the homo-tetrameric enzyme complex and the observed SAR is in keeping with the size and electronic constraints of these binding sites. Access to the corresponding sites in the human enzyme is blocked. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.10.002
• 作为产物：
  描述：

  5-iodo-1H-indole-2-carboxylic acid 在 N-甲基吗啉 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 、 乙醚 为溶剂， 反应 96.0h， 生成 1-(5-iodo-1H-indol-2-yl)ethanone
  参考文献：
  名称：

  [EN] ANTI-BACTERIAL PYRUVATE KINASE MODULATOR COMPOUNDS, COMPOSITIONS, USES, AND METHODS
  [FR] COMPOSÉS ANTIBACTÉRIENS MODULATEURS DE LA PYRUVATE KINASE, COMPOSITIONS, UTILISATIONS ET MÉTHODES ASSOCIÉES

  摘要：

  提供了具有A-C式结构的化合物。提供了这些化合物作为抗生素的用途，包括革兰氏阴性和革兰氏阳性微生物，以及涉及这些化合物的治疗方法和用途。

  公开号：

  WO2012051708A1

文献信息

• <i>gem</i> ‐Difluoroallylation of Aryl Halides and Pseudo Halides with Difluoroallylboron Reagents in High Regioselectivity
  作者：Shu Sakamoto、Trevor W. Butcher、Jonathan L. Yang、John F. Hartwig

  DOI：10.1002/anie.202111476

  日期：2021.12

  coupling of a difluoroallylboronate with aryl and heteroaryl halides and triflates provides a convenient and broadly applicable synthesis of difluoroallylarenes. The difluoroallyl boron reagent is formed by a copper-catalyzed defluorinative borylation of the inexpensive reagent 3,3,3-trifluoropropene, and the products undergo a wide range of reactions to a series of difluoro-substituted analogs of common

  二氟烯丙基硼酸酯与芳基和杂芳基卤化物和三氟甲磺酸酯的偶联提供了方便且广泛适用的二氟烯丙基芳烃的合成。二氟烯丙基硼试剂是通过铜催化的廉价试剂 3,3,3-三氟丙烯的脱氟硼基化形成的，并且产物经历广泛的反应，形成一系列常见的具有生物价值的结构单元的二氟取代的类似物。
• STAT6 inhibitors
  申请人：Board of Regents, The University of Texas System

  公开号：US10385080B2

  公开（公告）日：2019-08-20

  The present disclosure provides compounds that are useful for inhibiting the STAT6 pathway. Also provided are related pharmaceutical compositions and methods of using the compounds. In some embodiments, the compounds may be used to treat a disease such as, e.g., an allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease, or a cancer.

  本公开提供了可用于抑制 STAT6 通路的化合物。还提供了相关的药物组合物和使用这些化合物的方法。在一些实施方案中，化合物可用于治疗疾病，如过敏性肺病、过敏性鼻炎、慢性肺阻塞性疾病或癌症。
• STAT6 INHIBITORS
  申请人：Board of Regents, The University of Texas System

  公开号：US20180222931A1

  公开（公告）日：2018-08-09

  The present disclosure provides compounds that are useful for inhibiting the STAT6 pathway. Also provided are related pharmaceutical compositions and methods of using the compounds. In some embodiments, the compounds may be used to treat a disease such as, e.g., an allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease, or a cancer.